The molecular pathogenesis and management of bronchial carcinoids
Authors:
- Mehtap CakirMCMehtap Cakir
- Ashley GrossmanAGAshley Grossman
- 23 January 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 15 (4) , 457-491
Abstract
(2011). The molecular pathogenesis and management of bronchial carcinoids. Expert Opinion on Therapeutic Targets: Vol. 15, No. 4, pp. 457-491. doi: 10.1517/14728222.2011.555403Keywords
This publication has 228 references indexed in Scilit:
- MG-132 Inhibits Carcinoid Growth and Alters the Neuroendocrine PhenotypeJournal of Surgical Research, 2010
- Phosphatidylinositol 3-Kinase-Akt Signaling in Pulmonary Carcinoid CellsJournal of the American College of Surgeons, 2009
- Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell linesCancer, 2009
- Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathwayThe American Journal of Surgery, 2009
- PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcriptionLaboratory Investigation, 2009
- Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell linesCancer, 2008
- Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathwaysSurgery, 2007
- The α1 subunit of the sodium pump could represent a novel target to combat non‐small cell lung cancersThe Journal of Pathology, 2007
- Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?Cancer Chemotherapy and Pharmacology, 2006
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003